| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-414
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-41 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B33Y80-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B33Y10-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-3834
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/D01D5-0076 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-20 |
| filingDate |
2016-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2018-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2018536499-A |
| titleOfInvention |
System and method for optimized patient-specific tissue manipulation vascular graft |
| abstract |
It has been established that optimization of cell seeding on tissue engineered vascular grafts (TEVG) involves a reduction in TEVG's inflammatory response and a reduction in post-operative stenosis. Cell seeding increases TEVG patency in a dose-dependent manner, and TEVG patency is improved when more cells are seeded, but the incubation duration is minimal relative to TEVG patency. Shows only the impact. A method is provided for creating a patient specific TEVG that includes an optimal number of cells to maintain graft patency and reduce post-operative stenosis. A sealed single use, customizable system for TEVG seeding is also provided. Preferably, the system is custom designed based on patient-specific graft morphology so that cell seeding efficacy is increased. |
| priorityDate |
2015-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |